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Abstract
Aim: To evaluate the use of hybrid closed-loop glucose control with faster-acting
insulin aspart (Fiasp) in adults with type 1 diabetes (T1D).
Research Design and Methods: In a double-blind, multinational, randomized, crossover
study, 25 adults with T1D using insulin pump therapy (mean ± SD, age 38 ± 9 years,
HbA1c 7.4% ± 0.8% [57 ± 8 mmol/mol]) underwent two 8-week periods of unrestricted
living comparing hybrid closed-loop with Fiasp and hybrid closed-loop with standard
insulin aspart in random order. During both interventions the CamAPS FX closed-loop
system incorporating the Cambridge model predictive control algorithm was used.
Results: In an intention-to-treat analysis, the proportion of time sensor glucose was
in the target range (3.9–10.0 mmol/L; primary endpoint) was not different between
interventions (75% ± 8% vs. 75% ± 8% for hybrid closed-loop with Fiasp vs. hybrid
closed-loop with standard insulin aspart; mean-adjusted difference −0.6% [95% CI
−1.8% to 0.7%]; p < .001 for non-inferiority [non-inferiority margin 5%]). The propor-
tion of time with sensor glucose less than 3.9 mmol/L (median [IQR] 2.4% [1.2%–
3.2%] vs. 2.9% [1.7%–4.0%]; p = .01) and less than 3.0 mmol/L (median [IQR] 0.4%
[0.2%–0.7%] vs. 0.7% [0.2%–0.9%]; p = .03) was reduced with Fiasp versus standard
insulin aspart. There was no difference in mean glucose (8.1 ± 0.8 vs. 8.0 ± 0.8 mmol/L;
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p = .13) or glucose variability (SD of sensor glucose 2.9 ± 0.5 vs. 2.9 ± 0.5 mmol/L;
p = .90). Total daily insulin requirements did not differ (49 ± 15 vs. 49 ± 15 units/day;
p = .45). No severe hypoglycaemia or ketoacidosis occurred.
Conclusions: The use of Fiasp in the CamAPS FX closed-loop system may reduce
hypoglycaemia without compromising glucose control compared with standard insu-
lin aspart in adults with T1D.
K E YWORD S
artificial pancreas, aspart, closed-loop insulin delivery, continuous glucose monitoring, faster
insulin aspart, insulin pump therapy, type 1 diabetes
1 | INTRODUCTION
Hybrid closed-loop (HCL) systems are transforming the management
of type 1 diabetes (T1D)1–3 but their performance can be limited by
the comparatively slow absorption of subcutaneously administered
rapid-acting insulin analogues.4 Faster-acting insulins have been
developed that have the potential to further improve the efficacy and
safety of closed-loop insulin delivery systems.
Fast-acting insulin aspart (Fiasp) is insulin aspart in a new formula-
tion, to which two excipients have been added.5 L-arginine serves as a
stabilizing agent, while niacinamide is responsible for accelerated
absorption after subcutaneous administration. Pharmacokinetic and
pharmacodynamic studies have shown that administration of a Fiasp
bolus, by either subcutaneous injection or continuous subcutaneous
insulin infusion, is associated with earlier insulin exposure and action
and earlier offset of exposure than standard insulin aspart.5,6
Short studies of 2-week duration investigating Fiasp and ultra-rapid
lispro in the Minimed 670G hybrid closed-loop system did not show any
significant differences in glucose control when compared with standard
insulin.7,8 Improved postprandial glucose control was reported with Fiasp
compared with standard insulin aspart in the Medtronic advanced hybrid
closed-loop system during a 6-week open-label study, although overall
time in the target glucose range was not significantly different between
interventions.9 In a supervised inpatient study involving unannounced
exercise and unannounced meals, time in the target glucose range was
similar with Fiasp compared with standard insulin aspart in the GlucoSitter
closed-loop system, although postprandial glucose control was superior
with standard insulin aspart.10
We aimed to evaluate the use of Fiasp in the CamAPS FX hybrid
closed-loop system in adult pump users with T1D over a longer time
period. Based on available information, we hypothesized that closed-
loop with Fiasp would provide similar efficacy as closed-loop with
standard insulin aspart.
2 | RESEARCH DESIGN AND METHODS
2.1 | Study participants
Inclusion criteria included T1D as defined by the World Health Orga-
nization, age 18 years or over, insulin pump therapy for at least
6 months (with or without Flash glucose monitoring or continuous
glucose monitoring [CGM]) and an HbA1c of 10% or less
(≤86 mmol/mol). Key exclusion criteria included pregnancy, a total
daily insulin dose of 2.0 units/kg/day or higher and more than one
episode of severe hypoglycaemia within the 12 months prior to
enrolment.
Eligible adults were recruited from diabetes clinics at
Addenbrooke's Hospital (Cambridge, UK), Manchester Royal Infirmary
(Manchester, UK), Medical University of Graz (Austria) and Inselspital,
University Hospital of Bern (Switzerland).
2.2 | Study oversight
Prior to study commencement, approval was received from indepen-
dent research ethics committees in the UK, Austria and Switzerland,
and regulatory authorities in the UK (Medicines and Healthcare Prod-
ucts Regulatory Agency), Austria (Austrian Agency for Health and
Food Safety) and Switzerland (Swissmedic). Participants signed
informed consent before any study-related activities were com-
menced. Participants were reimbursed for their participation in the
study and travel expenses.
2.3 | Study design and procedures
The study (trial registration: NCT04055480) adopted a double-blind,
multicentre, multinational, randomized, two-period, crossover design
contrasting hybrid closed-loop glucose control using faster-acting
insulin (Fiasp; Novo Nordisk, Bagsvaerd, Denmark) versus hybrid
closed-loop using standard insulin aspart (Novo Nordisk) during
unrestricted living. Each intervention lasted 8 weeks and the order of
the two interventions was random. A 2–4-week run-in period pre-
ceded randomization, during which participants used the study insulin
pump and CGM system.
At enrolment, blood samples were taken for analysis of HbA1c.
At the start of the run-in period, participants received individual face-
to-face training lasting 2–3 h regarding the use of the study insulin
pump (Dana Diabecare RS; Sooil, South Korea) and CGM system
(Dexcom G6; Dexcom, San Diego, CA, USA). Closed-loop (Auto Mode)
functionality was disabled. At the end of the run-in period, compliance
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in the use of study pump and continuous glucose monitoring was
assessed.
Participants were randomly assigned to receive either 8 weeks of
hybrid closed-loop with standard insulin aspart followed by hybrid closed-
loop with Fiasp or vice versa. Permuted block randomization was applied.
Assignment was blinded to study participants and study personnel.
At the start of the first closed-loop period, participants attended
for training on the hybrid closed-loop system. Competency in using the
closed-loop system was assessed. Participants were provided with
blinded insulin vials and thereafter participants continued the study
intervention for the next 8 weeks in free-living settings without remote
monitoring or supervision. No restrictions were imposed on food intake,
travel or physical activity. Participants were advised to bolus 15 min
prior to eating throughout the study as per standard clinical practice.
No pump settings were pre-emptively changed prior to the start
of each study period as insulin type was unknown to the participants
and study personnel. All participants were provided with a 24-h tele-
phone helpline to contact the local study team in the event of study-
related issues.
2.4 | Closed-loop system
The CamAPS FX app (CamDiab, Cambridge, UK) resides on an
unlocked Android phone, receives sensor glucose data from the
Dexcom G6 transmitter, and uses a Cambridge adaptive model predic-
tive control algorithm to direct insulin delivery on the Dana Diabecare
RS pump. The CamAPS FX app acts as a CGM receiver and includes a
bolus calculator utilizing bolus settings downloaded from the insulin
pump and controlling meal bolus delivery on the insulin pump. Every
8 to 12 min, the adaptive control algorithm residing on the app calcu-
lates the insulin infusion rate, which is communicated wirelessly to
the study pump via a low-energy Bluetooth communication protocol.
The control algorithm is initialized using the participant's weight and
total daily insulin dose and, gradually, adapts its insulin dosing based
on observed glucose patterns. The default glucose target is
5.8 mmol/L and can be adjusted by participants as required between
4.4 and 11 mmol/L. Further details are provided in Supplementary
Appendix (Figure A1).
2.5 | Assays
HbA1c at recruitment was measured locally using an International
Federation of Clinical Chemistry and Laboratory Medicine-aligned
method and following National Glycohemoglobin Standardization Pro-
gram standards.
2.6 | Study endpoints
The primary endpoint was the proportion of time when glucose was
in the target range between 3.9 and 10.0 mmol/L during the study
periods as recorded by sensor glucose measurements. Secondary end-
points included mean sensor glucose; glucose variability measured by
the standard deviation and coefficient of variation; time spent at glu-
cose levels of less than 3.9, less than 3.5, less than 3.0, less than 2.8,
less than 10.0 and higher than 16.7 mmol/L; and insulin delivery (total,
basal and bolus amounts). Hypoglycaemia burden was additionally
assessed by the low blood glucose index. Secondary endpoints were
calculated over the whole study periods, weekly and monthly in each
intervention period and during daytime and night-time periods; day-
time was classified as 6:00 AM to 9:59 PM and night-time as 10:00
PM to 5:59 AM.
2.7 | Statistical analysis
This was an exploratory non-inferiority analysis aiming for 24 partici-
pants completing the study. The statistical analysis plan was agreed
by the investigators in advance. All analyses were carried out on an
intention-to-treat basis. Non-inferiority was assessed by comparing
the lower limit of 95% confidence interval for the mean difference in
the percentage of time with glucose levels in the target range
between 3.9 and 10.0 mmol/L to −5%. We analysed endpoints from
participants with a minimum of 48 h of sensor data in at least one
study period. The respective values obtained during the 8-week ran-
domized interventions were compared using a linear mixed model
adjusting for period as a fixed effect and site as a random effect. Base-
line values from the run-in period were included in the model. For
analyses conducted by time of day, a treatment by time of day inter-
action term was included in the model to assess whether the treat-
ment effect differed by time of day. Rank normal transformation
analyses were used for highly skewed endpoints. Endpoints are pres-
ented as mean ± SD for normally distributed values or as median
(interquartile range [IQR]) for non-normally distributed values. Out-
comes were calculated using GStat software, version 2.3 (University
of Cambridge, Cambridge, UK), and statistical analyses were carried
out using SAS software, version 9.4 (SAS Institute). A 5% significance
level was used to determine statistical significance. For secondary
analyses, the false discovery rate was controlled using the adaptive
Benjamini-Hochberg procedure.11 All p values are two-sided.
3 | RESULTS
From August 2019 to February 2020, 25 participants were recruited
and randomized (12 males, mean ± SD age 38 ± 9 years, duration of
diabetes 22 ± 12 years, HbA1c 7.4% ± 0.8% [57 ± 8 mmol/mol], and
total daily insulin 46 ± 13 units/day [46% basal, 54% bolus]) (Table 1).
The flow of participants through the trial is shown in Figure S2A. All
25 randomized participants completed the trial with at least 48 h of
sensor data in both periods.
Primary and secondary endpoints calculated using data from all ran-
domized participants are presented in Table 2. The primary endpoint, the
proportion of time sensor glucose was in the target range between 3.9
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TABLE 1 Characteristics of study participants at baseline
Overall (n = 25) Fiasp first (n = 13)
Standard insulin
aspart first (n = 12)
Age (years) 38 ± 9 37 ± 10 39 ± 8
Male, n (%) 12 (48) 5 (38) 7 (58)
Race/ethnicity, n (%)
White 23 (92) 12 (92) 11 (92)
Other 2 (8) 1 (8) 1 (8)
BMI (kg/m2) 26.0 (23.6, 28.5) 26.0 (23.6, 28.3) 26.0 (23.7, 31.6)
Duration of diabetes (years) 22 ± 12 18 ± 10 26 ± 13
HbA1c (%) 7.4 ± 0.8 7.6 ± 0.8 7.1 ± 0.7
HbA1c (mmol/Mol) 57 ± 8 59 ± 8 55 ± 8
Percent of time with sensor glucose level
3.9 to 10.0 mmol/L 61 ± 13 59 ± 10 64 ± 15
>10.0 mmol/L 35 ± 15 39 ± 12 32 ± 17
>16.7 mmol/L 2.8 (1.0, 4.3) 2.8 (1.3, 4.1) 2.3 (0.6, 5.8)
<3.9 mmol/L 2.4 (1.0, 4.6) 1.9 (0.6, 4.6) 2.8 (1.4%, 4.6)
<3.0 mmol/L 0.2 (0.1, 0.7) 0.2 (0.1, 0.4) 0.3 (0.2, 0.8)
Mean glucose (mmol/L) 9.1 ± 1.3 9.4 ± 1.2 8.8 ± 1.4
Glucose SD (mmol/L) 3.3 ± 0.6 3.4 ± 0.5 3.2 ± 0.8
Total daily insulin (units/day) 46 ± 13 45 ± 12 48 ± 16
Total daily basal insulin (units/day) 21 ± 7 21 ± 6 21 ± 9
Total daily bolus insulin (units/day) 25 ± 8 24 ± 8 26 ± 9
Abbreviation: BMI, body mass index.
Data are presented as mean ± SD or median (Q1, Q3) unless otherwise indicated. Glucose data are based on sensor glucose measurements.
TABLE 2 Glucose control and insulin delivery over 8 weeks of closed-loop with faster-acting insulin (Fiasp) and closed-loop with standard
insulin aspart
Fiasp (n = 25)
Standard insulin
aspart (n = 25) p value
95% CI for treatment
difference
% of time with sensor glucose level
3.9 to 10.0 mmol/L* 75 ± 8 75 ± 8 <.001** −0.6 (−1.8, 0.7)
<3.9 mmol/L 2.4 (1.2, 3.2) 2.9 (1.7, 4.0) .01 −0.3 (−0.5, −0.1)
<3.5 mmol/L 1.2 (0.5, 1.9) 1.7 (0.7, 2.3) .02 −0.3 (−0.5, −0.1)
<3.0 mmol/L 0.4 (0.2, 0.7) 0.7 (0.2, 0.9) .03 −0.3 (−0.6, −0.1)
<2.8 mmol/L 0.2 (0.1, 0.4) 0.4 (0.1, 0.5) .01 −0.4 (−0.6, −0.1)
>10.0 mmol/L 22 ± 9 21 ± 9 .13 1.2 (−0.2, 2.5)
>16.7 mmol/L 1.4 (0.4, 2.1) 1.2 (0.5, 1.6) .94 0.0 (−0.2, 0.2)
Mean glucose (mmol/L) 8.1 ± 0.8 8.0 ± 0.8 .13 0.10 (−0.02, 0.22)
Glucose SD (mmol/L) 2.9 ± 0.5 2.9 ± 0.5 .90 −0.00 (−0.08, 0.07)
Glucose CV (%) 36 ± 4 36 ± 4 .18 −0.5 (−1.3, 0.2)
Low blood glucose index 0.7 (0.5, 1.0) 0.9 (0.5, 1.1) .01 −0.3 (−0.5, −0.1)
Total daily insulin (units/day) 49 ± 15 49 ± 15 .45 0.6 (−1.0, 2.3)
Total daily basal insulin (units/day) 30 ± 13 29 ± 13 .14 1.3 (−0.3, 2.8)
Total daily bolus insulin (units/day) 19 ± 7 19 ± 6 .93 0.1 (−1.2, 1.3)
% time using closed-loop 95 (94, 97) 96 (92, 97) .98 0.1 (−0.6, 0.6)
% time using CGM 97 (96, 98) 97 (95, 98) — —
Abbreviation: CGM, continuous glucose monitoring; CV, coefficient of variation.
Data presented are mean ± SD or median (Q1, Q3) throughout the 8-week study periods. Glucose data are based on sensor glucose measurements. The
prespecified analysis plan did not include analyses of CGM use.
*Primary endpoint.
**p value is for non-inferiority; the non-inferiority margin is 5%.
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and 10.0 mmol/L, was not different between interventions (75% ± 8%
vs. 75% ± 8% for hybrid closed-loop with Fiasp vs. hybrid closed-loop
with standard insulin aspart, respectively; p < .001 for non-inferiority),
with a mean adjusted difference of −0.6 percentage points (95% CI −1.8
to 0.7). Figure 1A shows 24-h sensor glucose profiles.
There was no difference in mean glucose (8.1 ± 0.8
vs. 8.0 ± 0.8 mmol/L; p = .13) or glucose variability (SD of sensor glu-
cose 2.9 ± 0.5 vs. 2.9 ± 0.5 mmol/L; p = .90) between study interven-
tions (Table 2). The proportion of time sensor glucose was less than
3.9 mmol/L was reduced with Fiasp versus standard insulin aspart
(median 2.4 [IQR 1.2%–3.2%] vs. 2.9 [IQR 1.7%–4.0%]; p = .01), with
a mean adjusted difference of −0.3 percentage points in favour of
Fiasp (95% CI −0.5 to −0.1). The time spent with sensor glucose read-
ings below 3.5, 3.0 and 2.8 mmol/L, and the relative burden of
hypoglycaemia as measured by the low blood glucose index, were all
reduced with Fiasp compared with standard insulin aspart (Table 2).
There was high correlation of the time in the target glucose range
between hybrid closed-loop with Fiasp and hybrid closed-loop with
standard insulin aspart (Figure 1B).
Total daily insulin delivery was similar between interventions
(49 ± 15 vs. 49 ± 15 units/day for closed-loop with Fiasp vs. closed-
loop with standard insulin aspart, respectively; p = .45). There was no
difference in basal or bolus insulin delivery between study interven-
tions (Table 2). Approximately 60% of insulin was delivered as basal
insulin and 40% through user-initiated boluses during each
intervention.
Glucose sensor use and closed-loop use were high. Closed-loop
was in use for a median of 95% (IQR 94%–97%) of the time with Fiasp
and 96% (92%–97%) with standard insulin aspart (Table 2).
Secondary endpoints calculated for daytime and night-time
are shown in Table 3. There was no evidence that the effect of
treatment depended on the period of the day (daytime vs. night-
time). Sensor glucose measures and insulin measures remained
stable from week 1 of each intervention period and between
months of each intervention period (data not shown). There was
no evidence of a carryover effect between interventions when a
period by treatment interaction term was included in the
model (p = .85).
3.1 | Adverse events
No severe hypoglycaemia or diabetic ketoacidosis or other severe
adverse events were reported during the study. Four adverse events
were reported; two occurred during run-in, one during hybrid closed-
loop with Fiasp, and one during hybrid closed-loop with standard
insulin aspart. One event related to the study pump, which consisted
of a malfunctioning of the pump refill mechanism during a set change,
and which required pump replacement. All participants recovered fully
without clinical sequelae.
There were nine unscheduled contacts throughout the study that
occurred in five participants. Seven contacts were related to device
issues.
4 | DISCUSSION
This double-blind, multicentre, randomized, controlled trial investi-
gated the application of Fiasp in a hybrid closed-loop system in adults
with T1D over an 8-week period of unrestricted living. Our findings
show that use of Fiasp in the CamAPS FX hybrid closed-loop system
may offer additional benefit with a reduction in hypoglycaemia com-
pared with standard insulin aspart, without compromising overall
glycaemic control as measured by time in target glucose range, mean
glucose and glucose variability.
The results of the current study are consistent with observations
in shorter studies using the Minimed 670G hybrid closed-loop system
in terms of the lack of an effect of currently available faster-acting
insulins on overall measures of glucose control. However, our study
shows reduced hypoglycaemia with Fiasp and supports the applica-
tion of Fiasp in hybrid closed-loop systems in adults with T1D.7,8 It is
unclear if similar benefits can be obtained with other closed-loop sys-
tems and further longer studies with other closed-loop systems are
warranted.
F IGURE 1 (A) Sensor glucose levels (median, IQRs) during closed-
loop with Fiasp (n = 25; solid red line and red shaded area) and during
closed-loop with standard insulin aspart (n = 25; dashed black line and
grey shaded area). Dashed horizontal lines indicate the target glucose
range between 3.9 and 10 mmol/L. (B) Percentage of time spent in
target glucose range using Fiasp (FIA) compared with standard insulin
aspart (SIA; n = 25)
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Hypoglycaemia is a major concern for people with T1D, an impor-
tant cause of stress and anxiety and the main barrier to therapy inten-
sification and optimal glucose control.12 The reduction in time in
hypoglycaemia below 3.9 mmol/L with Fiasp equates to approxi-
mately 5 min/day. This effect size was observed at a very low glucose
threshold of 2.8 mmol/L, indicating that Fiasp reduces the exposure
to the lowest glucose levels which is then propagated to
hypoglycaemia exposure across higher glucose thresholds. A nomi-
nally greater reduction of hypoglycaemia with Fiasp was observed
during the daytime period, suggesting the benefits may be attributable
to faster offset of insulin action around mealtime boluses. The use of
the highly adaptable Cambridge closed-loop algorithm and the longer
study duration may be reasons why this effect was observed in our
study compared with the study conducted by Hsu et al.7 The fre-
quency of clinically significant hypoglycaemia is often comparatively
low in clinical trial settings, and it is probable that hypoglycaemia
occurs less frequently in study cohorts than in real-world populations.
Therefore, we consider the difference we observed to be clinically
important when interpreting the outcomes of this study in the context
of real-world clinical practice.
The performance of the CamAPS FX hybrid closed-loop system
was notable with an increase in the time in the target glucose range
from 61% during the run-in period to 75% during the study interven-
tion period, an improvement observed within the first week after
commencement of hybrid closed-loop irrespective of insulin type
(data not shown). Time spent in hypoglycaemia was comparable
between baseline (2.4%) and closed-loop study periods (2.4% and
2.9%). A similar time in the target glucose range (75%–78%) was
reported with the Minimed 670G Fiasp study although this was over
a shorter duration in a cohort with tighter glycaemic control at base-
line (median HbA1c 7.1%).7
There was no difference in glycaemic control between daytime
and night-time in our study; however, this was probably because of
the definition of night-time (10:00 PM), when postprandial hyper-
glycaemia may still be encountered, and this is supported by the 24-h
sensor glucose profiles (Figure 1).
The very high time spent in closed-loop during the study (≥95%)
reflects the usability of the system and is a key factor to realizing the
glycaemic benefits of closed-loop insulin delivery.13
The strengths of our study include the multinational, double-
blind, crossover design with each participant acting as their own
control, undertaken over a longer duration than previous studies
investigating closed-loop with faster-acting insulin. This is the only
study that has shown a reduction in hypoglycaemia with Fiasp in a
hybrid closed-loop system. The study was performed without remote
monitoring or close supervision, thereby assessing real-world use and
supporting generalizability of findings. The limitations include a com-
paratively small total number of participants, and a study population
with good glycaemic control at baseline (mean HbA1c 7.4%). The group
randomized to receive standard insulin aspart first had superior glucose
control and more time in hypoglycaemia at baseline, but given the cross-
over study design with each participant acting as their own control, this
TABLE 3 Daytime and night-time glucose control and insulin delivery during hybrid closed-loop with faster-acting insulin (Fiasp) and standard
insulin aspart









aspart (n = 25)
% of time with sensor glucose level
3.9 to 10.0 mmol/L 75 ± 8 75 ± 8 75 ± 11 76 ± 9 .98
<3.9 mmol/L 2.6 (1.2, 3.7) 3.1 (1.7, 4.8) 2.0 (1.2, 2.8) 2.2 (1.3, 3.1) .98
<3.5 mmol/L 1.2 (0.5, 1.8) 1.6 (0.8, 2.6) 1.0 (0.6, 1.4) 1.1 (0.6, 1.7) .98
<3.0 mmol/L 0.4 (0.1, 0.7) 0.6 (0.2, 0.9) 0.3 (0.1, 0.6) 0.4 (0.2, 0.9) .98
<2.8 mmol/L 0.2 (0.1, 0.3) 0.4 (0.1, 0.5) 0.2 (0.1, 0.4) 0.3 (0.1, 0.6) .98
>10.0 mmol/L 22 ± 9 22 ± 9 22 ± 11 21 ± 10 .88
>16.7 mmol/L 1.1 (0.4, 2.4) 1.2 (0.5, 1.8) 1.3 (0.4, 2.4) 0.9 (0.2, 1.7) .79
Mean glucose (mmol/L) 8.0 ± 0.8 8.0 ± 0.8 8.1 ± 0.9 8.0 ± 0.9 .57
Glucose SD (mmol/L) 2.9 ± 0.5 2.9 ± 0.5 2.9 ± 0.6 2.9 ± 0.6 .98
Glucose CV (%) 36 ± 4 36 ± 3 35 ± 5 36 ± 5 .98
Low blood glucose index 0.8 (0.5, 1.1) 0.9 (0.5, 1.2) 0.6 (0.5, 0.9) 0.7 (0.6, 1.0) .98
Total daily insulin (units/day) 38 ± 11 37 ± 11 12 ± 5 11 ± 5 .98
Total daily basal insulin (units/day) 20 ± 9 19 ± 9 10 ± 4 10 ± 4 .57
Total daily bolus insulin (units/day) 18 ± 6 18 ± 5 1 ± 1 1 ± 1 .98
Abbreviation: CV, coefficient of variation.
Data presented are mean ± SD or median (Q1, Q3) throughout the 8-week study periods. Glucose data are based on sensor glucose measurements.
*p value for treatment-by-time of day interaction.
1394 BOUGHTON ET AL.
was unlikely to have impacted on study outcomes, particularly as no car-
ryover effect between the two intervention periods was observed.
Future studies evaluating hybrid closed-loop with Fiasp in young
children, where hypoglycaemia is a major concern, are warranted. Fur-
thermore, studies contrasting hybrid closed-loop with Fiasp to hybrid
closed-loop with other faster-acting insulins including ultra-rapid
lispro and insulin analogues under development may show additional
benefits.14
In conclusion, hybrid closed-loop glucose control using the
CamAPS FX app with Fiasp is effective and safe in adults with T1D,
and may offer additional benefit in terms of hypoglycaemia reduction
compared with standard insulin aspart without compromising overall
glucose control.
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